stockrow
Saturday 7 November 2026
Export TRAW’s income statement to Excel — free account
Traws Pharma, Inc.
TRAW Healthcare Biotechnology
Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −45.5%
- Free cash flow
- −25.5%
Quarter to June 2026, against a year earlier
0.23
0.01
+4.55%
Follow TRAW
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 4 | — | — |
| (795.86%) | (37.35%) | (4,281.57%) | (336.30%) | ||
| (93.51%) | 33.87% | (108.38%) | (123.55%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(572.84%) | (190.66%) | 195.70% | 2,367.19% | |
Average Days of Receivables |
0.00 | 486.58 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.21) | (2.21) | (1.44) | (1.06) | |
Free Cash Flow |
(19.47) | (18.18) | (15.32) | (16.85) | |
| Other line items | |||||
Cash ROIC |
(177.54%) | (569.88%) | 703.58% | (251.22%) | |
Accounts Receivable Turnover |
0.00 | 1.02 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 426.67% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 299.44% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 25.58% | 0.00% | 0.00% | |
Operating CF/Net income |
1.95 | (3.02) | 1.04 | 1.01 | |
Depreciation/Fixed assets |
2.71 | 8.71 | 17.33 | 29.40 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.35 | 0.00 | 0.00 | |
Operating CF per Share |
(2.21) | (2.21) | (1.44) | (1.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026